Pharmaxis (ASX:PXS) - CEO, Gary Phillips (left)
CEO, Gary Phillips (left)
Source: Pharmaxis
Market Herald logo


Be the first with the news that moves the market
  • The first dose level of Pharmaxis’ (PXS) PXS-5505 drug shows strong inhibition of two targets enzymes in cancer patients
  • Pharmaxis is trialling the drug as a potential new treatment for myelofibrosis, a bone marrow cancer that causes blood cells to stop being produced
  • The company has recruited the second dose cohort and, after 28 days of dosage, the safety will be reassessed before moving to the final and highest dose
  • The dose escalation phase will determine what the optimal dose of PXS-5505 is for the six-month expansion study which will include 24 patients
  • Company shares are up 10.7 per cent to trade at 8.3 cents

Pharmaxis (PXS) has received initial data from its phase 1c clinical trial that’s studying a potential new treatment for myelofibrosis.

Myelofibrosis is a bone marrow cancer which causes scar tissue to build up, leading to the loss of production of red and white blood cells and platelets.

Positively, the first dose level of the company’s lead drug, PXS‐5505, has shown strong inhibition of two target enzymes, LOX and LOXL2, in patients.

The trial aims to demonstrate the PXS-5505 drug as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment.

Company CEO, Gary Phillips, was pleased with the results.

“We are delighted to see that along with excellent tolerability we are achieving levels of LOX and LOXL2 inhibition in myelofibrosis patients that are already exceeding those levels seen in the preclinical models of myelofibrosis.”

In the preclinical models, PXS‐5505 showed improvements in blood cell count, diminished spleen size and reduced bone marrow fibrosis.

“Comparing these results with those achieved in the phase one study with healthy volunteers, we are now very confident that we will achieve a level of inhibition of the lysyl oxidase enzyme family that allows us to fully test the clinical relevance of these targets in myelofibrosis patients in the upcoming six‐month dose expansion study,” Mr Phillips said.

Pharmaxis has already recruited the second dose cohort and dosing of all patients across the Australia and South Korea sites has begun.

After 28 days on this second dose, the safety and pharmacokinetics will be assessed before starting myelofibrosis patients on the final and highest dose. The dose escalation phase will determine what the optimal dose of PXS-5505 is for the six-month expansion study which will include. 24 patients.

Sites in other countries, including the US, are currently being engaged ahead of the dose expansion phase commencing recruitment later this year.

Company shares were up 10.7 per cent to trade at 8.3 cents at 1:44 pm AEST.

PXS by the numbers
More From The Market Herald
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.